Apixaban bei krebsassoziierter VTE – Testen Sie Ihr Wissen

Bei Frau T. (60 Jahre; 1,80 m; 55 kg) wurden vor zwei Monaten ein fortgeschrittenes Adenokarzinom des Ösophagus ohne detektierbare Expression des Programmed Cell Death-Ligand 1 (PDL-1) diagnostiziert und daraufhin eine ambulante Chemotherapie mit Platin-Fluoropyrimidin eingeleitet.

Referenzen

  1. Beyer-Westendorf J et al. Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism. Dtsch Arztebl Int 2019; 116(3):31–8.
  2. Deutsche Gesellschaft fuer Haematologie und medizinische Onkologie, Onkopedia Leitlinien. Onkopedia Leitlinien - Thromboembolien bei Tumorpatienten (früher: Venöse Thromboembolien (VTE) bei Tumorpatienten); 2020 [cited 2022 Sep 6]. Available from: URL: https://www.onkopedia.com/de/onkopedia/guidelines/thromboembolien-bei-tumorpatienten-frueher-venoese-thromboembolien-vte-bei-tumorpatienten/@@guideline/html/index.html.
  3. Raskob GE et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378(7):615–24.
  4. Young AM et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 2018; 36(20):2017–23.
  5. Agnelli G et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med 2020; Apr 23;382(17):1599-1607.
  6. Ageno W et al. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thromb Haemost 2021 [cited 1/13/2021]; 121(05):616–24.
  7. Agnelli G et al. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. Thromb Haemost 2022; 122(5):796–807.
  8. Stevens SM et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report - Executive Summary. Chest 2021; 160(6):2247–59.
  9. Dt. Gesellschaft für Angiologie – Gesellschaft für Gefäßmedizin. AWMF S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Stand: 2023. AWMF Registernummer 065 – 002 - gültig bis 13.02.2028.
  10. Fachinformationen Eliquis® 5 mg / 2,5 mg, aktueller Stand.
  11. Steffel J et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace 2021; 42:373.
  12. Kakkos SK et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg 2021 [cited 2021 Dec 3]; 61(1):9–82. Available from: URL: https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930868-.
  13. McBane RD et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. Eur J Haematol 2020; 104(2):88–96.
  14. ClinicalTrials.gov. API-CAT Study for APIxaban Cancer Associated Thrombosis (API-CT) [cited 2023 Feb 7]. Available from: URL: https://clinicaltrials.gov/ct2/show/NCT03692065?
  15. Larsen T-L et al. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up. J Thromb Haemost 2022; 20(5):1166–81.